Expression of c-erbB-2, p53 and c-myc proteins in male breast carcinoma: Comparison with traditional prognostic factors and survival

• Main Authors: M. Mourão Netto, A.F. Logullo, S. Nonogaki, R.R. Brentani, M.M. Brentani
• Format: Article
• Language: English
• Published: Associação Brasileira de Divulgação Científica 2001-07-01
• Series: Brazilian Journal of Medical and Biological Research
• Subjects: p53; c-myc; c-erbB-2; male breast cancer
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000700008

There are few data evaluating biological markers for men with breast cancer. The purpose of the present study was to analyze the expression of the oncogenes c-erbB-2 and c-myc and of the suppressor gene p53 by immunohistochemical techniques in archival paraffin-embedded tissue blocks of 48 male breast cancer patients, treated at the A.C. Camargo Cancer Hospital, São Paulo, SP, Brazil. The results were compared with clinicopathological prognostic features. Immunopositivity of c-erbB-2, p53 and c-myc was detected in 62.5, 16.7 and 20.8% of the cases analyzed, respectively. Estrogen and progesterone receptors were positive in 75 and 69% of the cases, respectively. Increasing staging was statistically associated with c-erbB-2 (P = 0.04) and weakly related to p53 positivity (P = 0.06). No significant correlation between specific survival rate (determined by the log rank test) and the molecular markers analyzed was found, whereas the number of compromised lymph nodes and advanced TNM (tumor, node, metastasis) staging were associated with diminished survival.